https://www.selleckchem.com/products/abt-199.html
Whether AR-V7 expression can predict the response in patients with metastatic hormone-sensitive prostate cancer (mHSPC) who receive androgen deprivation therapy (ADT) remains to be explored. To evaluate the predictive value of AR-V7 expression in the prognosis of mHSPC patients receiving ADT. In this multicenter prospective cohort study, 310 mHSPC patients commencing ADT were enrolled. Standard immunohistochemical staining was used to assess AR-V7 protein expression in biopsy tissues collected before initiation of ADT. Kaplan-Meier surv
Me gusta
Comentario
Compartir
